GSTM1 and anemia (phenotype): Bessarab et al. [23] were the authors of a randomized, open-label study of the course of hemoglobin (Hb) leveling after roxadustat administration in patients with anemia (Hb <10.0 g/dL) treated with hemodialysis (HD) or peritoneal dialysis (PD).